GMA 304
Alternative Names: GMA-304Latest Information Update: 27 Nov 2020
At a glance
- Originator Gmax Biopharm
- Class Antihypertensives; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Atrial natriuretic factor receptor A agonists; Endothelin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Pulmonary arterial hypertension
Most Recent Events
- 03 Nov 2020 GMA 304 is available for licensing as of 03 Nov 2020. http://www.gmaxbiopharm.com/job.html
- 03 Nov 2020 Early research in Pulmonary arterial hypertension in China (Parenteral) (Gmax Biopharm pipeline, November 2020)